REVENUES (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
|---|
| REVENUES |
|
| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Gross product sales |
|
$ |
56,322 |
|
$ |
38,585 |
|
$ |
143,728 |
|
$ |
105,239 |
Discounts and allowances |
|
|
(17,395) |
|
|
(11,456) |
|
|
(45,348) |
|
|
(30,484) |
Total product sales, net |
|
|
38,927 |
|
|
27,129 |
|
|
98,380 |
|
|
74,755 |
Revenues from collaborations: |
|
|
|
|
|
|
|
|
|
|
|
|
License revenue |
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
— |
Milestone revenue |
|
|
— |
|
|
75 |
|
|
— |
|
|
75 |
Delivery of drug supplies, royalty and others |
|
|
6,380 |
|
|
930 |
|
|
13,302 |
|
|
5,260 |
Total revenues from collaborations |
|
|
16,380 |
|
|
1,005 |
|
|
23,302 |
|
|
5,335 |
Government contracts |
|
|
— |
|
|
— |
|
|
— |
|
|
1,000 |
Total revenues |
|
$ |
55,307 |
|
$ |
28,134 |
|
$ |
121,682 |
|
$ |
81,090 |
|
| Schedule of product revenue allowance and reserve categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2024 |
|
$ |
8,236 |
|
$ |
3,517 |
|
$ |
3,931 |
|
$ |
15,684 |
Provision related to current period sales |
|
|
34,565 |
|
|
9,167 |
|
|
884 |
|
|
44,616 |
Credit or payments made during the period |
|
|
(31,363) |
|
|
(6,441) |
|
|
(304) |
|
|
(38,108) |
Balance as of September 30, 2024 |
|
$ |
11,438 |
|
$ |
6,243 |
|
$ |
4,511 |
|
$ |
22,192 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2023 |
|
$ |
6,213 |
|
$ |
2,636 |
|
$ |
3,296 |
|
$ |
12,145 |
Provision related to current period sales |
|
|
23,150 |
|
|
5,932 |
|
|
623 |
|
|
29,705 |
Credit or payments made during the period |
|
|
(21,504) |
|
|
(5,631) |
|
|
(172) |
|
|
(27,307) |
Balance as of September 30, 2023 |
|
$ |
7,859 |
|
$ |
2,937 |
|
$ |
3,747 |
|
$ |
14,543 |
|
| Schedule of revenues from product sales disaggregated by customers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
2024 |
|
2023 |
|
|
2024 |
|
2023 |
McKesson Corporation |
|
|
43% |
|
|
49% |
|
|
|
44% |
|
|
46% |
Cencora Inc. (formerly ASD Healthcare) |
|
|
19% |
|
|
18% |
|
|
|
20% |
|
|
20% |
Cardinal Health, Inc. |
|
|
* |
|
|
28% |
|
|
|
15% |
|
|
27% |
Kissei |
|
|
23% |
|
|
* |
|
|
|
14% |
|
|
* |
|